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Abstract 
Photoacoustic (PA) tomography enables multiscale, multicontrast and high-resolution imaging of 
biological structures. In particular, contrast-enhanced PA imaging offers high-sensitivity noninva-
sive imaging of neovessel sprout formation and nascent tubules, which are important biomarkers 
of malignant tumors and progressive atherosclerotic disease. While gold nanoparticles or nano-
rods have been used as PA contrast agents, we utilized high-density copper oleate small molecules 
encapsulated within a phospholipid surfactant (CuNPs) to generate a soft nanoparticle with PA 
contrast comparable to that from gold. Within the NIR window, the copper nanoparticles pro-
vided a 4-fold higher signal than that of blood. ανβ3-integrin targeting of CuNPs in a MatrigelTM 
angiogenesis mouse model demonstrated prominent (p<0.05) PA contrast enhancement of the 
neovasculature compared with mice given nontargeted or competitively inhibited CuNPs. Fur-
thermore, incorporation of a Sn 2 lipase-labile fumagillin prodrug into the CuNP outer lipid 
membrane produced marked antiangiogenesis in the same model when targeted to the 
ανβ3-integrin, providing proof of concept in vivo for the first targeted PA – drug delivery agent. 
Key words: copper, nanoparticle, near-infrared imaging, photoacoustic imaging, angiogenesis 
imaging, anti-angiogenic therapy. 
Introduction 
As an important component of an expanding 
vascular network the neovasculature can be viewed as 
a biomarker of inflammation associated with tumor 
aggressiveness or atherosclerotic plaque progression. 
[1-3] To date, noninvasive imaging of angiogenesis 
has been essentially a preclinical endeavor, although 
imaging candidates have reached the clinical testing 
level for MRI and nuclear medicine. Nuclear medicine 
probes, although exquisitely specific for neovascular 
biosignatures, such as the ανβ3-integrin, are not spe-
cific to angiogenesis, since this adhesion molecule is 
activated on numerous cell types present in tumors or 
atherosclerotic lesions. [4-6] By comparison, MRI 
paramagnetic nanoparticle agents are often vascu-
lar-constrained by size and very specific for neoen-
dothelial expression of ανβ3-integrin, but such agents 
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have experienced other roadblocks in the clinic. [7] 
Photoacoustic molecular imaging offers noninvasive 
vascular-constrained detection of angiogenic bi-
omarkers with very high resolution imaging of the 
neovasculature. 
 Different imaging modalities have different 
characteristic resolution limits, with microscopic im-
ages having the highest resolution for thin specimens. 
For biomedical instrumentation, ultra-high spatial 
resolution MRI at 3.0T and high resolution CT pro-
vide in vivo blood vessel images but with a poorer 
resolution, in the range of 200 to 500 μm, which is 
inadequate for discrete neovessel imaging. [8-12] 
Photoacoustic (PA) imaging combines the advantages 
of ultrasound imaging and optical imaging and offers 
high depth-to-resolution ratios at different spatial 
scales, ranging from organelles to organs, [13] as well 
as unique and important physiological assessments, 
such as differential circulating blood oxygenation 
levels.  
 Previous studies have confirmed that PA imag-
ing’s utility can be markedly extended with exoge-
nous contrast agents. [14-16] In many instances, these 
contrast agents have been based on gold cubes, 
spheres, or rods with particle sizes greater than the 
renal clearance threshold (<8 to 10 nm), creating dif-
ficult translational challenges when proving 
long-term safety in man. Gold nanobeacons (120-160 
nm) were developed to achieve the large absorption 
cross-sections of bigger solid gold particles by sus-
pending a multitude of small gold nanoparticles (3-5 
nm) in a hydrophobic matrix encapsulated with 
phospholipid (160 nm). [17] Moreover, the optical 
absorption wavelength of nanoparticles was tunable 
well into the NIR optical window, minimizing en-
dogenous absorption and maximizing PA imaging 
depth.  
 However, the pressure of healthcare economics 
has placed an emphasis on driving the costs of imag-
ing studies down, and we have thus sought lower cost 
biocompatible alternatives to gold. We hypothesized 
that nanoparticles entrapping high densities of or-
ganically soluble small molecular weight copper 
complexes could provide an inexpensive and effective 
approach to neovascular targeted PA imaging. The 
choice of copper as a cheaper, biocompatible alterna-
tive to gold was independently supported by a recent 
report describing nontargeted crystalline copper sul-
fide nanoparticles as PA contrast agents for deep tis-
sue imaging at 1064 nm. [18] In this research, a soft 
noncrystalline ανβ3-targeted copper-oleate nanoparti-
cle (ανβ3-CuNP) was developed and its PA imaging 
signal with respect to blood and the previously re-
ported gold nanobeacons was characterized [17] as a 
function of NIR wavelength and with varying nano-
particle concentrations. The in vivo efficacy of 
ανβ3-CuNPs for high-resolution imaging of mouse 
neovasculature was examined in a Matrigel™ model 
of angiogenesis. Furthermore, the theranostic antian-
giogenic potential of ανβ3-CuNPs incorporating a 
novel Sn 2 lipase-labile fumagillin prodrug (Fum-PD) 
was also studied. [19]  
Materials and Methods  
Reagents 
Unless otherwise listed, all solvents and reagents 
were purchased from Aldrich Chemical Co. (St. Louis, 
MO) and used as received. Anhydrous chloroform 
and methanol were purchased from Aldrich Chemical 
Co. Poly (styrene-b-acrylic acid) (PS-b-PAA) was 
purchased from Polymer Source Inc. (Montreal, 
Canada). High purity egg yolk phosphatidylcholine 
was purchased from Avanti Polar Lipids, Inc. Cho-
lesterol and cooper oleate were purchased and used 
as received from Aldrich Chemical Co. (St. Louis, 
MO). Sorbitan monolaurate was purchased from Al-
drich. Argon and nitrogen (Ultra High Purity: UHP, 
99.99%) were used for storage of materials. The Spec-
tra/Por membrane (Cellulose MWCO: 20,000 Da) 
used for dialysis was obtained from Spectrum Medi-
cal Industries, Inc. (Laguna Hills, CA).  
Preparation of Sn 2 lipase labile Fumagillin 
prodrug  
Synthesis of the Sn 2 prodrug was accomplished 
in two steps: 1) saponifying fumagillin dicyclohex-
ylamine salt to fumagillol, and 2) esterifying the 
product with 
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine 
(PAzPC). [19] Briefly, fumagillin dicyclohexylamine 
salt (NCI) in 1:1 methanol:water was treated with 35% 
NaOH, stirred in an ice bath for 2 h, warmed to room 
temperature, treated with another equivalent of 35% 
NaOH, and then stirred in an ice bath until the start-
ing material was not detected by TLC (∼4 h). After 
evaporating the methanol and solubilizing in ethyl 
acetate, the mixture was extracted with 5% citric acid, 
brine, bicarbonate, and brine again, then dried with 
MgSO4 and concentrated in vacuo. The crude product 
was purified with activated charcoal in acetonitrile 
and then filtered through a celite pad. (Yield: a color-
less solid, 59 mg (70%). 1H NMR (CD3OD): δ 5.20 (t, 
1H), 4.3 (m, 1H), 3.42 (m, 1H), 3.38 (s, 3H), 2.88 (d, 1H), 
2.63 (t, 1H), 2.51 (d, 1H), 2.1–2.3 (m, 2H), 2.2 (m, 1H), 
1.89 (d, 1H), 1.7–1.9 (m, 2H), 1.8 (d, 3H), 1.7 (d, 3H), 
1.17 (s, 3H), 0.96 (m, 1H). HR-MS found: MH+ (283.3). 
 A solution of C16-09:0 (COOH) PC 
1-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine, 
followed by 4-dimethylaminopyridine (DMAP) and 
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N, N'-dicyclohexyl-carbodiimide (DCC), was added 
to fumagillol in dry dichloromethane. The reaction 
mixture was stirred overnight at ambient temperature 
then passed over a short pad of silica gel using 
EtOAc/n-hexane. The filtered solvent was removed in 
vacuo, and the oil residue was purified by column 
chromatography on SiO2 using EtOAc/n-hexane for 
elution to yield the fumagillin prodrug (Fum-PD) 
compound as a pale yellowish solid (yield: 54%). 1H 
NMR (CDCl3): δ 0.88 (t, 3H), 1.22–1.37 (m, 37H), 
1.58–1.96 (m, 20H), 2.26–2.60 (m, 7H), 3.40 (m, 12H), 
3.48 (m, 3H), 3.86–4.00 (m, 4H), 4.10–4.37 (m, 5H), 5.21 
(m, 1H). HR-MS found: 930.6 (MH+). 
Preparation of copper nanoparticles  
Copper-oleate (260 mg) dissolved in toluene was 
suspended in almond oil (4 ml), gently vortexed to 
homogeneity, and filtered through a small bed of 
cotton. The solvent was evaporated under reduced 
pressure at 45°C, leaving a mixture containing 65 mg 
of copper oleate per ml. The surfactant co-mixture 
included high-purity egg yolk phosphatidylcholine 
(91.9 mol%), cholesterol (8 mol%), and 
ανβ3-peptidomimetic antagonist conjugated to 
PEG2000-phosphatidylethanolamine (0.1 mol%; Kere-
os, St. Louis, MO, USA). Therapeutic ανβ3-CuNPs 
incorporated the Sn 2 lipase labile fumagillin prodrug 
(2.28 mol%) at the equimolar expense of phosphati-
dylcholine. The surfactant co-mixtures were dissolved 
in chloroform, evaporated under reduced pressure, 
dried in a 40°C vacuum oven overnight, and dis-
persed into water by probe sonication. This suspen-
sion was combined with the copper oleate-almond oil 
mixture (20% v/v), distilled deionized water (77.3% 
w/v), and glycerin (1.7%, w/v) and continuously 
processed at 20,000 psi for 4 min with an S110 Micro-
fluidics emulsifier (Microfluidics, Newton, MA, USA) 
at 4°C. The copper nanoparticles (CuNPs) were dia-
lyzed against water using a 20-kDa MWCO cellulose 
membrane for a prolonged period of time and then 
passed through a 0.45 µm Acrodisc syringe filter (Pall 
Life Sciences, East Hills, NY, USA). To inhibit lipid 
oxidation, the CuNPs were stored under an argon 
atmosphere, typically at 4°C. (Figure 1) 
 
 
Figure 1. Synthesis and physiochemical characterization of CuNPs. (a) schematic of the concept of CuNPs with fumagillin prodrug; (b) hydrodynamic particle size distribution 
from DLS. The nominal hydrodynamic diameters of αvβ3-CuNPs and fumagillin prodrug CuNPs were typically 190 nm ± 15 nm, (c). Anhydrous state atomic force microscopy 
(AFM) image of CuNPs (drop-deposited on glass) Average height: 80 nm ± 12 nm. (d). EDX spectrum generated from the SEM image. 
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The nominal hydrodynamic diameter (Dh) of the 
αvβ3-CuNPs and the fumagillin prodrug CuNPs was 
determined by dynamic light scattering (DLS) meas-
urements (Brookhaven ZetaPlus, Brookhaven In-
struments Corporation) in aqueous solution, were 
typically 190 nm ± 15 nm (std error), with a polydis-
persity of 0.09 ± 0.01, and a zeta potential of -23 ± 06 
mV. Incorporation of the prodrug at 2.28 mol% (~0.5 
mM) within the surfactant co-mixture had negligible 
impact on particle sizes.  
The ανβ3-integrin antagonist was a quinalone 
nonpeptide developed by Lantheus Medical Imaging 
(Billerica, MA, USA) and synthesized by Kereos (U.S. 
Patent 6,511,648 and related patents). The vitronectin 
antagonist was reported and characterized as the 
111In-DOTA conjugate RP478 and cyan 5.5 homologue 
TA145. [20] The homing specificity of the ligand was 
demonstrated and characterized with Matrigel plug 
implanted in Rag1tm1Mom Tg (Tie-2-lacZ) 182-Sato and 
C57Bl/6 mice. [14]  
The reference gold nanobeacons (GNBs) used in 
this study were prepared and characterized as pre-
viously described. [14] The GNBs were in a 20 vol% 
suspension with a nominal particle size of 160 nm, 
containing 6120 gold-oleate particles (3-5 
nm)/nanobeacon, with a gold content of 1080 µg/g.  
 Matrigel™ plug mouse model of angiogenesis 
All animal studies were conducted in accordance 
with protocols approved by the Animal Care and Use 
Committee of Washington University Medical School.  
Athymic nude-mice (Harlan Labs, Indianapolis, 
IN) with body weights ranging from 23 to 27 g were 
obtained. Anesthesia was induceod by ketamine (100 
mg/ml) and xylazine (20 mg/ml), which were main-
tained with 0.5% to 1% isoflurane in oxygen, with 
ventilator support and supplemental temperature 
support. Matrigel (0.5 ml, BI, Biosciences, San Jose, 
CA, USA) enriched with fibroblast growth factor-2 
(500 nm/ml; Sigma-Aldrich, St. Louis, MO, USA) and 
heparin was implanted subcutaneously along the 
mouse flank. The nude mice (n = 12) were randomly 
distributed into four groups to test (1) the efficacy of 
ανβ3-CuNPs for PA molecular imaging of angiogene-
sis in vivo and (2) the efficacy of ανβ3-CuNPs with 
Fum-PD as a theranostic agent. For the first test, three 
groups were compared on day 18 using PA imaging: 
(1) ανβ3-CuNPs without Fum-PD (integrin targeted, 
n=3); (2) nontargeted CuNPs (nonspecific entrapment, 
n=3) and (3) ανβ3-almond oil nanoparticle (NP) fol-
lowed after 10 min by ανβ3-CuNPs without Fum-PD 
(specific competition, n=3). To address the second 
question within the same experimental design, (4) 
ανβ3-CuNPs with Fum-PD were administered on days 
11 and 15, following Matrigel implantation, and the 
effect on angiogenesis was assessed on day 18 with 
ανβ3-CuNPs without Fum-PD (n=3). All treatments 
were injected via tail vein at 2 μl/g body weight of the 
20 vol% nanoparticle suspensions. For each animal 
dynamic PA imaging was performed before injection 
(baseline, 0 min) and then repeated every 30 min over 
270 minutes post-injection.  
Photoacoustic imaging  
 A reflection-mode PA imaging system using 
dark-field ring-shaped illumination [21] was pumped 
by a Q-switched Nd:YAG (LS-2137; Lotis TII) laser 
with <15-ns pulse duration and a 10-Hz pulse repeti-
tion rate. The light energy on the sample surface was 
controlled to conform to the American National 
Standards Institute (ANSI) standard for maximum 
permissible exposure. A 10 MHz central frequency, 
spherically focused (2.54 cm focus length, 1.91 cm 
diameter active area element, and 68% nominal 
bandwidth (One way -6 dB bandwidth is ~96%) ul-
trasonic transducer (V315; Panametrics-NDT, Wal-
tham, MA, USA) acquired the generated PA signals. 
The signal was amplified by a low-noise amplifier 
(5072PR; Panametrics-NDT), and recorded using a 
digital oscilloscope (TDS 5054; Tektronix, Beaverton, 
OR, USA) with 50-MHz sampling. PA signal fluctua-
tions due to pulse-to-pulse energy variation were 
compensated for by signals from a photodiode 
(DET110; Thorlabs, Newton, NJ, USA), which sam-
pled the energy of each laser pulse. 
 Prior to in vivo imaging, two preliminary ex-
periments were performed. In preliminary experi-
ment 1, individual samples of CuNPs (20 vol%) and 
bovine blood (hct. ~45%) were placed into individual 
transparent plastic tubes (ID, 510 µm) and imaged by 
the PA system at 767 nm. The A-line signals from 
these two tubes are presented in Figure 2 as super-
imposed waveforms. 
 In preliminary experiment 2, the transparent 
Tygon tubes (ID, 510 µm) were filled with CuNPs (20 
vol %), GNBs (20 vol%), and whole bovine blood (hct. 
~45%). They were imaged at varying wavelengths 
between 730 nm and 830 nm. As an extension of this 
experiment, CuNPs were serially diluted from 6.0 µM 
to 0.17 µM and imaged at 750 nm, 760 nm, 770 nm, 780 
nm, and 790 nm. In each experiment, the maximum 
amplitudes of the A-line signals (n=5) at each wave-
length were averaged. 
 Finally, in vivo imaging of angiogenesis in the 
Matrigel Plug model was performed. A linear trans-
lation stage (XY-6060; Danaher Motion, Rad ford, VA, 
USA) was used for raster scanning to obtain 3-D PA 
data. A computer controlled the stage and synchro-
nized it to the data acquisition. To shorten the data 
acquisition time, a continuous scan was used without 
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signal averaging. Typical scanning values are as fol-
lows: voxel dimensions, 0.1 × 0.2 mm; laser pulse 
repetition rate, 10 Hz; acquisition time, ~20 min.  
In vivo imaging was performed using ventilated 
anesthetized mice with shaved flanks, constantly 
warmed to 37°C by a heating block and positioned 
immediately beneath the transparent clear membrane. 
PA imaging was performed at 767 nm, as previously 
used for GNB in vivo. [14] Similarly, the ves-
sel-integrated PA amplitude, calculated by integrat-
ing the enveloped PA signal amplitude over the blood 
vessel region, was used to quantify the degree of an-
giogenesis. The vessel-integrated PA amplitude was 
normalized to that of the pretreatment level during 
the analysis. 
Statistical Analysis 
Data were analyzed using analysis of variance 
(GraphPad Prism Ver. 6.03) (p < 0.05). Data are pre-
sented as the mean ± standard error of the mean un-
less otherwise stated. 
Results  
Given the inherently strong PA signal of hemo-
globin, the efficacy of PA contrast agents for targeted 
molecular imaging of neovascular integrin expression 
is dependent on the strength and differentiation of its 
signal from the blood background. The PA signal of 
CuNPs (20 vol%) was compared with whole bovine 
blood (45% hct.) at 767 nm. As seen in Figure 2, the 
time-aligned PA signal of the copper NP emulsion 
was markedly greater than that of the bovine blood at 
767. The peak-to-peak signal of the CuNPs (2.3 a.u.) 
was 4-fold greater than that of blood (0.58 a.u.) at 767 
nm, suggesting that the PA signal of neovascular 
bound CuNPs could be readily detectable in vivo.  
 GNBs have been previously shown to produce 
strong PA contrast in vivo when applied to sentinel 
lymph node imaging or when targeted to neovascu-
lature in vivo. [14, 17, 22, 23] The PA signal enhance-
ment of CuNPs relative to blood (45% hct.) was com-
pared to the signal of GNBs relative to blood across a 
NIR frequency range of 730 nm to 830 nm (Figure 3) 
on an equal nanoparticle number basis. Over almost 
the entire spectrum, the CuNPs signal strength rela-
tive to blood was around 5-fold greater with a no-
ticeable decline beyond 820 nm. In general, the PA 
ratios of GNBs and CuNPs were very similar except 
between 760 nm and 790 nm, with the greatest diver-
gence between GNBs and CuNPs at 770 nm, at which 
point the gold contrast result was nearly twice that of 
copper. GNB particles experienced the same declining 
results as CuNPs from 800 nm and beyond.  
 The concentration dependence of CuNPs’ sig-
nals as a function of frequency was examined. CuNPs 
were serially titrated from 6.0 µM to 0.17 µM and 
studied at NIR wavelengths between 750 nm and 790 
nm (Figure 4 (A)). PA amplitude decreased with re-
ductions in CuNP concentration level, but the mag-
nitude of signal diminishment was generally less than 
the percent change in CuNP level. This was particu-
larly notable for the higher concentrations, between 
6.0 µM and 1.5 µM. The magnitude of the CuNP’s PA 
signal was greatest at 750 nm and 760 nm. At higher 
wavelengths, the magnitude of the CuNP signal 
trended lower, with the greatest contrast loss seen at 
the lower CuNP concentrations. It can be calculated 
from the extinction coefficient spectrum shown in 
Figure 4 (B) that the extinction coefficient of CuNPs at 
700 nm was 1.3 times as strong as that at around 770 
nm. However, the laser energy at 767 nm (the peak of 
laser energy) is an order of magnitude stronger than 
that at 700 nm. Therefore, neovascular imaging signal 
peaks around 767 nm.  
 
 
Figure 2. Overlay of PA signals from CuNPs (20 vol%) and blood (whole bovine 
blood, hct. 45%;). CuNPs and blood samples were placed into transparent TygonTM 
tubes (ID = 510 µm) and imaged by the PA system at 767 nm. The peak-to-peak PA 
signal from the CuNPs was 4 times greater than that of the blood at 767 nm. 
 
 
Figure 3. Equal-nanoparticle-based ratio of peak-to-peak PA signal amplitudes from 
previously reported gold nanobeacons (20 vol%) [14] and CuNPs (20 vol%) to those 
of whole bovine blood (hct. 45%) over the 730 – 830 nm range. Over the whole 
spectrum, PA signals of CuNPs were markedly greater than those of the blood. In 
general, the PA ratios of GNBs and CuNPs relative to blood were similar. 
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Figure 4. (A) PA signals from copper nanoparticles (20 vol%) in a transparent Tygon tube filled with serially diluted copper nanoparticles (0.17 µM, 0.38 µM, 0.75 µM, 1.5 µM, 
3.0 µM, 6.0 µM) at laser wavelengths from 750 nm to 790 nm, with 10 nm step size. A nonlinear relationship between the PA amplitude and CuNP concentration was observed. 
(B) Normalized extinction coefficient spectrum of the CuNPs (20 vol%) at laser wavelengths from 600 nm to 800 nm. 
 
Figure 5. In vivo PA images of the Matrigel plug area implanted in 4 groups of mice 18 days prior to imaging. (A)-(B) Targeted CuNPs group: mice received αvβ3-CuNPs just before 
PA imaging. The enhanced neovasculature is marked by arrows in B. (C)-(D):Nontargeted CuNPs group: mice received nontargeted CuNPs right before PA imaging 
(E)-(F):Competition group: mice received a competitive dose of αvβ3-oil only NP (1:1) 10 minutes prior to imaging, followed by αvβ3-CuNPs right before imaging. (G)-(H) Fum-PD 
group: mice received αvβ3-CuNPs with Fum-PD 11 and 15 days after the Matrigel implantation, and αvβ3-CuNPs w/o Fum-PD right before PA imaging. Comparing the PA images 
of the nontargeted, competition, and Fum-PD groups at 0 min and 170 min, very little change in PA signals can be found. For all PA images, laser wavelength = 767 nm. 
 
To provide robust assessment of PA signal en-
hancement due to the CuNPs, in vivo neovascular 
imaging was studied in the Matrigel plug model in 
mice. Mice implanted with Matrigel™ 18 days pre-
viously received either ανβ3-CuNPs, nontargeted 
CuNPs, or ανβ3-CuNP preceded by 10 minutes with a 
competitive dose ανβ3-oil only NPs (1:1). As seen in 
Figure 5, at 0 min, forming neovessels were observed 
by the inherent PA contrast imparted by erythrocyte 
hemoglobin. The magnitude of the signal varied 
among animals with the extent of neovascular prolif-
eration. Following ανβ3-CuNP injection, the magni-
tude of the PA signal in these immature tubules 
clearly increased, and numerous incomplete vascular 
sprouts appeared, as we have previously reported for 
GNBs. [14] The formation of the neovessel shoots de-
picted an early evolution stage of a dense and irregu-
lar microvasculature. In contradistinction to the ani-
mals receiving ανβ3-CuNPs, those given nontarget-
ed-CuNPs had very little increase in the ves-
sel-integrated PA amplitude. As shown, a minimal 
passive accumulation of the CuNPs in the forming 
bridges and sprouts combined with a modest amount 
of blood pool enhancement relative to the neovessel 
tubules at 0 min. We have previously reported that 
blood pool enhancement for GNBs in the intact mi-
crovasculature surrounding the Matrigel implant was 
negligible, [14] but within the plug, the slow moving 
blood may be associated with very slow washout. In 
the competition group at 170 min, very little change in 
the PA signal from the forming vascular tubules or 
sprouts was observed. In this group, the pretreatment 
binding of the ανβ3-oil NPs appeared to have blocked 
most of the receptors for the ανβ3-CuNP and even 
precluded significant passive accumulation. Figure 6 
presents the average change in the vessel-integrated 
 Theranostics 2015, Vol. 5, Issue 2 
 
http://www.thno.org 
130 
PA amplitude between the three treatment groups, 
showing that the ανβ3-CuNPs increased PA contrast, 
while the nontargeted-CuNP did not (p<0.05). More-
over, the specificity of targeting the neovasculature 
was again demonstrated by the low vessel-integrated 
PA amplitude measured in the competition group 
versus the ανβ3-CuNP group (p<0.05), and even rela-
tive to the nontargeted control. Dynamic accumula-
tion of PA contrast measured in the ανβ3-CuNP group 
increased progressively over the 230 minutes post 
injection interval (Figure 7). 
 
 
Figure 6. Vessel-integrated PA amplitude (normalized to the baseline, i.e., the 
vessel-integrated PA amplitude at 0 min) at 170 min post-injection for four groups of 
mice. The vessel-integrated PA amplitude for the αvβ3-targeted group increased more 
than that of the other three groups (*P<0.05). Almost no increase in vessel-integrated 
PA amplitude was measured in the competition group, and a slight increase was 
observed in the non-targeted and Fum-PD groups. 
 
 
Figure 7. Vessel-integrated PA amplitude vs. post-injection time for the αvβ3-CuNPs 
group. The vessel-integrated PA amplitude increased progressively over the 230 min 
post injection interval. 
 
In a second aspect of the Matrigel™ angiogenesis 
experiment, fumagillin-prodrug (Fum-PD), [24, 25], 
was incorporated into the phospholipid surfactant at 
2.28 mol%. The chemical synthesis, characterization, 
and in vivo effectiveness of Fum-PD incorporated into 
perfluorocarbon nanoparticles has been previously 
reported. [19, 26] ανβ3-CuNP (2 µl/g) incorporating 
Fum-PD was administered on days 11 and 15 post 
Matrigel™ implant, and the vessel-integrated PA am-
plitude in these animals was determined on day 18. At 
baseline, the amount of neovasculature observed by 
PA imaging was sparse, but no more so than that in 
the other groups. Moreover, following ανβ3-CuNP 
injection there was little sprouting enhancement at 
170 minutes. As shown collectively in Figures 5 and 6, 
the vessel-integrated PA amplitude change was simi-
lar to that measured in the nontargeted-CuNP group, 
and appeared related to modest particle accumulation 
in the nascent tubules, with less signal related to 
sprout formation. Although drug delivery and imag-
ing were not performed simultaneously to minimize 
the differential animal handling between the groups, 
these results illustrated the potential of CuNPs as ve-
hicles for drug delivery and diagnosis.  
Discussion 
Photoacoustic imaging has demonstrated broad 
applications in the imaging and physiological char-
acterization of the vasculature, particularly the mi-
crovasculature [13, 27], and microvascular expansion 
driven by brain tumor hypoxia [28]. The vascular 
endothelium provides numerous “road-signs” re-
flecting its developmental stage, as seen for the neo-
vasculature, or its state of activation, as seen with in-
flammation. In each instance, specific PA characteri-
zation depends on molecular imaging through the 
recognition of unique endothelial biomarkers. [15, 16, 
22, 29-33] In the present study, sparse activated 
ανβ3-integrin was selected as a biomarker of angio-
genesis. While we have previously reported dynamic 
imaging of the forming neovasculature with gold 
nanobeacons, the high and unpredictable cost of gold, 
and the unclear long-term safety of larger nonmetab-
olizable nanoparticles, such as carbon fullerenes or 
nanotubes, led to the design and development of 
CuNPs. While free copper can elicit systemic toxicity, 
CuNPs are comprised of high densities of small or-
ganometallic complexes that can be eliminated 
through the bile or urine, minimizing the risk poten-
tial for this agent. [34] In the present study, CuNPs 
offered comparable PA contrast enhancement, on an 
equal particle basis, to GNBs both in vitro and in vivo.  
 In vivo PA imaging was performed at 767 nm, 
which was optimal for the previously targeted GNB 
agent, but the spectral assessments of CuNP relative 
to blood and as a function of particle concentration 
suggest 740 or 750 nm may be preferred for targeting 
sparse epitopes like adhesion molecules. Also, the 
time for maximum neovascular signal was found to 
be nearly 4 hours in the Matrigel model, but similar 
particles administered in vivo for deeper-tissue angi-
ogenesis imaging with MRI were shown to provide 
minimal targeting benefit after 2 hours. [35, 36] The 
difference likely relates to vascular vasoconstriction 
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with reduced blood flow to the skin in the subcuta-
neous Matrigel implant model, which is aggravated 
by the cooling effects of acoustically coupling the PA 
probe to the body during anesthesia, despite provi-
sion of supplemental heating to maintain core body 
temperatures. Lastly, CuNPs were designed to be 
vascular constrained agents to reduce nonspecific 
signal generated by interactions with extravascular 
cells expressing the ανβ3-integrin. Close examination 
of the 170-minute PA images in Figure 5 showed neg-
ligible extravasation of the particles. Although much 
attention has been attributed to the leakiness of an-
giogenesis, even in the sprouting regions where the 
neovasculature is essentially open-ended, no evidence 
of nanoparticle accumulation beyond the tips of the 
forming neovessel branches was noted. Moreover, 
this was a consistent observation, regardless of 
whether the nanoparticles were integrin-targeted or 
not.  
Fumagillin prodrug was incorporated into the 
phospholipid surfactant of CuNPs and demonstrated 
to elicit anti-angiogenic effects in this Matrigel model. 
Microanatomically, the treatment virtually eliminated 
the rich web of sprouts in the mice receiving 
ανβ3-CuNPs without Fum-PD. “Pruning” of neovas-
culature was first suggested by Jain in a visionary 
manner, but in this study, the concept was visually 
apparent. [37-39] Despite all of the extensive clinical 
research on the effects and benefits of an-
ti-angiogenesis therapy in cancer and selected other 
pathologies, virtually all of the work has centered on 
vascular endothelial growth factor (VEGF) inhibition. 
While VEGF is a clear driver of angiogenesis, it elicits 
pleotropic effects and is not solely responsible for 
neovascularization. [40] Moreover, VEGF is produced 
by a variety of cell types, making effective blockade of 
the growth factor challenging. Typically, relatively 
high dosages of medicants are used clinically and 
these treatments have well known side-effects. [41]  
 As reported by others, fumagillin is an antian-
giogenic agent which is specific for proliferating en-
dothelial cells, but its clinical analogue, TNP-470, 
possessed only antidotal effectiveness in the clinic at 
the high doses required, which were accompanied by 
numerous toxicities, including neurocognitive dys-
function. [42-44] Fumagillin can be effectively incor-
porated into the phospholipid surfactant of nanopar-
ticles for targeted delivery of anti-angiogenesis ther-
apy through a mechanism referred to as “contact fa-
cilitated drug delivery” (CFDD) at a small fraction of 
the dosages previously used systemically. [2, 45, 46] 
Tethering of the lipid-encapsulated nanoparticle to 
the target cell surface facilitates the interaction and 
hemifusion of the two lipid membranes, which af-
fords the passive transfer of the drug and phospho-
lipids from the nanoparticle surface to the outer leaflet 
of the target cell membrane. The drug is then trans-
located to the inner leaflet through an ATP-dependent 
mechanism. [47, 48] CFDD eliminates the need for 
particle internalization with subsequent endosomal 
drug payload escape.  
 However, pharmacokinetic studies showed that 
fumagillin dissolved into the lipid membrane was 
substantially lost prematurely during circulation to 
the target neovasculature, despite its effectiveness in 
vivo. Fum-PD was developed to address this early 
release by coupling the drug through the Sn 2 acyl 
position (i.e., the stereospecific hydroxyl group of the 
second carbon of glycerol). Subsequent transfer of the 
monolayer components into the target cell membrane 
allows cytosolic phospholipases to enzymatically 
cleave the Sn 2 ester and release the drug, allowing it 
to diffuse into the cytosol for effect. Fum-PD as well as 
other similar prodrug compounds is incorporated 
stably into the hydrophobic aspects of the particle 
membrane. Importantly, Sn 2 lipase-labile prodrugs 
within the particle lipid membrane are stable in blood 
and plasma, even in the presence of excess exogenous 
lipase, and do not passively exchange to 
co-circulating RBC. [49] The results of the present 
research show the first example of a systemically tar-
geted antiangiogenic drug delivery with a photoa-
coustic contrast nanoparticle. Given the rapid devel-
opments in hardware and software for PA imaging, 
one can envision numerous medical applications for 
low-cost CuNPs particles to target neovascular or 
alternative endothelial biosignatures for diagnostic 
and theranostic purposes.  
 Unlike current VEGF inhibitors, fum-
agillin-prodrug specifically targeted to angiogenic 
vessels suppresses angiogenesis, clinical disease, and 
inflammation in a preclinical model of rheumatoid 
arthritis (RA). [50] Enhanced endothelial nitric oxide 
(NO) modulates local macrophage inflammatory ac-
tivity through NO activation of AMP-activated pro-
tein kinase (AMPK). In vivo, NO-induced AMPK ac-
tivation increased autophagy by inhibiting mamma-
lian target of rapamycin (mTOR) activity. Increased 
autophagy mediated the degradation of IkappaB ki-
nase (IKK) and suppressed NF-κB. The suppression of 
NF-κB was associated with diminished inflammatory 
cytokine release. Importantly, the NO mediated inhi-
bition of inflammation was reversed in vitro and in 
vivo by the co-administration of N(G)-nitro-L-arginine 
methyl ester (L-NAME), a nitric oxide synthase in-
hibitor. These unique anti-angiogenic and an-
ti-inflammatory properties of Fum-PD nanotherapy 
may be applicable to the treatment of other angio-
genesis-dependent diseases.  
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Conclusion 
 Soft copper oleate nanoparticles were synthe-
sized and conceptually shown to offer effective pho-
toacoustic contrast comparable to gold-based agents, 
but at a much lower cost and higher material availa-
bility. CuNPs possessed strong PA contrast relative to 
blood from 730 nm to 830 nm, which was similar to 
the PA signal response of gold nanobeacons relative 
to blood overall. In the Matrigel angiogenesis model, 
ανβ3-CuNPs markedly enhanced neovessel tubules 
and identified a myriad of incomplete emergent neo-
vascular sprouts, which were not well detected or 
specifically differentiated as angiogenesis with in-
herent PA imaging. ανβ3-CuNPs effectively delivered 
fumagillin-prodrug, a potent anti-angiogenic therapy, 
in vivo, providing the first example of a systemically 
targeted drug delivery therapy with a photoacoustic 
contrast agent.  
 Abbreviations  
PA: photoacoustic; CuNPs: copper oleate 
nanoparticles; Sn 2: glycerophospholipids use “sn” 
notation, stereospecific numbering. By convention the 
hydroxyl group of the second carbon of glycerol (Sn 2) 
is on the left on a Fischer projection; NIR: near 
infrared; ανβ3: alpha v beta 3 integrin; MRI: magnetic 
resonance imaging; CT: computed tomography; PET: 
positron emission tomography; αvβ3-CuNP: 
αvβ3-targeted copper oleate nanoparticle; Fum-PD: 
fumagillin prodrug; PS-b-PAA: poly(styrene-b-acrylic 
acid); DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid; Tie-2: endothelium-specific receptor 
tyrosine kinase; GNB: gold nanobeacons; PAzPC: 
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine; 
DMAP: dimethylaminopyridine; DCC: 
dicyclohexylcarbodiimide; DLS: dynamic light 
scattering; NP: nanoparticle; ID: inner diameter; hct: 
hematocrit; VEGF: vascular endothelial growth factor; 
CFDD: contact facilitated drug delivery. RA, 
rheumatoid arthritis. NO, nitric oxide. AMPK, 
AMP-activated protein kinase. mTOR, mammalian 
target of rapamycin. IKK, IkappaB kinase. L-NAME, 
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